Microbiome engineering: unlocking therapeutic potential in inflammatory bowel disease

Area of Science:

• Microbiology
• Synthetic Biology
• Gastroenterology

Background:

• The human gut microbiome comprises non-pathogenic microbes crucial for host homeostasis.
• Microbiome engineering utilizes synthetic biology to develop novel therapeutics.
• Inflammatory bowel disease (IBD) is a target for microbiome-based interventions.

Purpose of the Study:

• To review recent advances in engineering microbes for IBD therapy.
• To highlight synthetic biology tools for reprogramming gut microorganisms.
• To discuss the potential of engineered microbes as living therapeutics.

Main Methods:

• Engineering symbiotic bacteria with synthetic gene circuits for targeted drug delivery.
• Utilizing bacteriophages to modulate dysbiotic gut microbiota.
• Developing yeast-based systems for metabolic interventions, such as butyrate production.

Main Results:

• Engineered microbes can sense pathological signals and deliver targeted therapies.
• Synthetic gene circuits enable precision treatment in bacteria.
• Phage therapy and yeast systems offer novel approaches for IBD management.

Conclusions:

• Engineered microbes represent a promising frontier for IBD treatment.
• Challenges in biocontainment, genetic stability, and clinical translation need addressing.
• Emerging strategies like outer membrane vesicles (OMVs) show potential for immunomodulation.